HIMS Quantitative Stock Analysis

Validea's guru fundamental report indicates that HIMS & HERS HEALTH INC (HIMS) receives a 75% rating based on their Small-Cap Growth Investor model, which is based on the published strategy of Motley Fool; this suggests some interest in the stock due to its solid fundamentals and strong price performance, though a rating above 80% typically indicates more significant interest. The analysis highlights strengths in profit margin, relative strength, sales and EPS growth, and insider holdings, but identifies weaknesses related to cash and cash equivalents, the Fool Ratio, average shares outstanding, and sales.

Analysis

HIMS & HERS HEALTH INC (HIMS), identified as a large-cap growth stock in the Biotechnology & Drugs sector, received a 75% rating from Validea's Small-Cap Growth Investor model, which is based on the Motley Fool strategy. This rating suggests a degree of interest, though it falls below the 80% level typically indicating more significant alignment with the strategy's criteria. The fundamental analysis presents a mixed profile: HIMS successfully met criteria for profit margin, relative strength, year-over-year growth in sales and EPS, insider holdings, cash flow from operations, profit margin consistency, R&D as a percentage of sales, inventory to sales, accounts receivable to sales, and its long-term debt/equity ratio. Conversely, the company did not meet the model's standards for cash and cash equivalents, "THE FOOL RATIO" (P/E to Growth), average shares outstanding, sales, daily dollar volume, and income tax percentage. The failure on metrics such as "Sales" and "Daily Dollar Volume" might be partly attributable to HIMS's large-cap classification being assessed against a model designed for small-cap companies, a nuance warranting consideration.

Key Decisions for Investors

• Investors should view the 75% rating for HIMS from the Small-Cap Growth model as an indicator for further investigation, recognizing it reflects only moderate interest and highlights several unmet criteria alongside its strengths.
• Careful examination of the 'FAIL' metrics, particularly 'Cash and Cash Equivalents' which could signal liquidity constraints, and 'THE FOOL RATIO' (P/E to Growth) which raises valuation questions, is crucial.
• Given HIMS is a large-cap stock assessed by a small-cap model, 'FAIL' scores on size-sensitive criteria like 'Sales' and 'Daily Dollar Volume' may stem from this model mismatch rather than fundamental weaknesses, requiring investors to contextualize these specific findings.